Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for RedHill Biopharma (RDHL) over the last 8 years, with Q2 2025 value amounting to $10.5 million.

  • RedHill Biopharma's Current Deferred Revenue fell 1534.01% to $10.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.5 million, marking a year-over-year decrease of 1534.01%. This contributed to the annual value of $9.3 million for FY2024, which is 1282.15% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Current Deferred Revenue is $10.5 million, which was down 1534.01% from $9.3 million recorded in Q4 2024.
  • RedHill Biopharma's Current Deferred Revenue's 5-year high stood at $47.9 million during Q4 2022, with a 5-year trough of $9.3 million in Q4 2024.
  • In the last 5 years, RedHill Biopharma's Current Deferred Revenue had a median value of $26.0 million in 2021 and averaged $25.2 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 6742.63% in 2021, then plummeted by 7774.39% in 2023.
  • RedHill Biopharma's Current Deferred Revenue (Quarter) stood at $30.7 million in 2021, then soared by 55.87% to $47.9 million in 2022, then plummeted by 77.74% to $10.7 million in 2023, then dropped by 12.82% to $9.3 million in 2024, then grew by 13.49% to $10.5 million in 2025.
  • Its last three reported values are $10.5 million in Q2 2025, $9.3 million for Q4 2024, and $12.5 million during Q2 2024.